(Q37738743)

22 August 2017

1 reference

title

Metabolic syndrome associated with schizophrenia and atypical antipsychotics (English)

1 reference

22 August 2017

0 references

1 reference

Mehrul Hasnain

1

1 reference

22 August 2017

Sonja K Fredrickson

series ordinal

2

1 reference

22 August 2017

W Victor R Vieweg

series ordinal

3

1 reference

22 August 2017

Anand K Pandurangi

series ordinal

4

1 reference

22 August 2017

1 June 2010

1 reference

22 August 2017

Current diabetes report

1 reference

22 August 2017

10

1 reference

22 August 2017

3

1 reference

22 August 2017

209-216

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-010-0112-8

22 August 2017

0 references

cites work

A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients

1 reference

12 December 2020

A UK audit of screening for the metabolic side effects of antipsychotics in community patients

1 reference

12 December 2020

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

1 reference

12 December 2020

Diet, diabetes and schizophrenia: review and hypothesis.

1 reference

12 December 2020

Metabolic syndrome in people with schizophrenia: a review.

1 reference

12 December 2020

A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone

1 reference

12 December 2020

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

12 December 2020

The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia

1 reference

12 December 2020

Banting Lecture 1988. Role of insulin resistance in human disease. 1988.

1 reference

12 December 2020

Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?

1 reference

12 December 2020

Weight gain in antipsychotic-naive patients: a review and meta-analysis

1 reference

12 December 2020

Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications

1 reference

12 December 2020

Efficacy of behavioural interventions in managing atypical antipsychotic weight gain

1 reference

12 December 2020

The metabolic syndrome and schizophrenia

1 reference

12 December 2020

Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis.

1 reference

12 December 2020

Metabolic profile of antipsychotic-naive individuals with non-affective psychosis

1 reference

12 December 2020

Obesity, serious mental illness and antipsychotic drugs.

1 reference

12 December 2020

Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions

1 reference

12 December 2020

Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes

1 reference

12 December 2020

Diagnosis and Classification of Diabetes Mellitus

1 reference

12 December 2020

Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia

1 reference

12 December 2020

Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

Prevalence of metabolic syndrome among Australians with severe mental illness

1 reference

12 December 2020

Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care

1 reference

12 December 2020

Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies

1 reference

12 December 2020

Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials.

1 reference

12 December 2020

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline

1 reference

12 December 2020

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors

1 reference

12 December 2020

Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients

1 reference

12 December 2020

Diabetes mellitus and schizophrenia: historical perspective

1 reference

12 December 2020

Quality of diabetes care among adults with serious mental illness.

1 reference

12 December 2020

Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects

1 reference

12 December 2020

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

1 reference

12 December 2020

Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population

1 reference

12 December 2020

Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder

1 reference

12 December 2020

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

12 December 2020

New-onset type-2 diabetes associated with atypical antipsychotic medications.

1 reference

12 December 2020

Pharmacological management of atypical antipsychotic-induced weight gain.

1 reference

12 December 2020

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal

1 reference

12 December 2020

The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation

1 reference

12 December 2020

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

1 reference

12 December 2020

Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia

1 reference

12 December 2020

Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study

1 reference

12 December 2020

Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions

1 reference

12 December 2020

Schizophrenia and increased risks of cardiovascular disease

1 reference

12 December 2020

10.1007/S11892-010-0112-8

Identifiers

DOI

1 reference

22 August 2017

1 reference